As of 2026-04-05, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -38.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 2,378.69 mil USD. TXG's TTM EBITDA according to its financial statements is -62.36 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.5x - 17.5x | 13.6x |
| Forward P/E multiples | 24.0x - 29.8x | 27.6x |
| Fair Price | (2.37) - 3.76 | 0.41 |
| Upside | -110.6% - -83.2% | -98.2% |
| Date | EV/EBITDA |
| 2026-04-02 | -38.15 |
| 2026-04-01 | -37.57 |
| 2026-03-31 | -35.89 |
| 2026-03-30 | -32.98 |
| 2026-03-27 | -32.31 |
| 2026-03-26 | -34.25 |
| 2026-03-25 | -35.24 |
| 2026-03-24 | -32.98 |
| 2026-03-23 | -31.61 |
| 2026-03-20 | -30.07 |
| 2026-03-19 | -30.05 |
| 2026-03-18 | -27.94 |
| 2026-03-17 | -29.46 |
| 2026-03-16 | -26.59 |
| 2026-03-13 | -30.89 |
| 2026-03-12 | -31.20 |
| 2026-03-11 | -34.32 |
| 2026-03-10 | -34.32 |
| 2026-03-09 | -35.24 |
| 2026-03-06 | -35.03 |
| 2026-03-05 | -36.73 |
| 2026-03-04 | -38.23 |
| 2026-03-03 | -38.74 |
| 2026-03-02 | -39.81 |
| 2026-02-27 | -39.62 |
| 2026-02-26 | -37.74 |
| 2026-02-25 | -32.68 |
| 2026-02-24 | -31.53 |
| 2026-02-23 | -31.10 |
| 2026-02-20 | -31.08 |
| 2026-02-19 | -31.71 |
| 2026-02-18 | -32.49 |
| 2026-02-17 | -30.55 |
| 2026-02-13 | -29.52 |
| 2026-02-12 | -28.27 |
| 2026-02-11 | -31.63 |
| 2026-02-10 | -31.63 |
| 2026-02-09 | -30.38 |
| 2026-02-06 | -30.53 |
| 2026-02-05 | -28.66 |
| 2026-02-04 | -31.45 |
| 2026-02-03 | -31.90 |
| 2026-02-02 | -33.27 |
| 2026-01-30 | -33.78 |
| 2026-01-29 | -35.01 |
| 2026-01-28 | -35.59 |
| 2026-01-27 | -36.69 |
| 2026-01-26 | -38.50 |
| 2026-01-23 | -38.25 |
| 2026-01-22 | -39.91 |